MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$830K
Free Cash flow
-$3,604K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Stock-based compensation
    • Accrued wages and fringe benefit...
    • Others
Negative Cash Flow Breakdown
    • Sales and marketing
    • General and administrative
    • Research and development
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
21,702
19,251
17,615
17,063
Purchases of inventory
3,483
2,778
2,496
2,668
Other cost of sales
452
745
808
519
Gross profit
17,767
15,728
14,311
13,876
Sales and marketing
13,573
12,841
11,938
12,053
General and administrative
5,971
6,061
7,090
7,226
Research and development
5,078
5,629
5,691
3,748
Total operating expenses
24,622
24,531
24,719
23,027
Operating loss
-6,855
-8,803
-10,408
-9,151
Interest expense
1,463
1,424
1,250
1,269
Other income, net
688
-395
20
-2,751
Loss before income taxes
-7,630
-10,622
-11,638
-13,171
Income tax expense
33
-11
-17
16
Net loss
-7,663
-10,611
-11,621
-13,187
Fair value of common stock issued related to loan amendment
-
-
0
2,152
Debt issuance costs
0
319
-
-
Change in fair value of loan facility
-211
-198
555
922
Change in fair value of warrant liabilities
-24
625
-617
-40
Depreciation and amortization
605
627
700
574
Stock-based compensation
1,988
1,101
1,373
2,777
Non-cash lease expense
240
233
228
224
Loss on fixed asset disposal
-188
-53
-5
-247
Loss on patent disposal
0
2
0
5
Remeasurement and foreign currency transaction loss
-10
-9
0
-17
Excess and obsolete inventory related charges
-65
-57
-115
-152
Provision for credit losses
14
0
7
-11
Amortization of premium of marketable securities
-43
-77
-84
-31
Non-cash changes in the fair value of nqdc plan
-135
-19
134
-28
Trade and other receivables
5
-799
-81
2,341
Prepaids and other current assets
721
90
-509
118
Inventory
-765
-752
-198
-144
Corporate-owned life insurance ('coli') asset
-187
0
0
0
Other long-term assets
60
-77
-464
235
Accounts payable and accrued expenses
-762
-1,786
983
861
Accrued wages and fringe benefits
951
57
2,018
-2,146
Current non-qualified deferred compensation liability
234
262
-63
-30
Other current liabilities
911
-481
30
292
Operating lease liability
-159
-154
-189
-249
Non-qualified deferred compensation plan liability
-142
-61
174
100
Contract liabilities
-9
-8
-8
-8
Net cash used in operating activities
-3,496
-10,072
-5,438
-5,219
Purchase of marketable securities
0
3,937
1,963
7,886
Maturities of marketable securities
4,000
6,000
2,000
3,500
Purchase of plant and equipment
108
19
-674
934
Capitalized software development costs
-
-
635
-
Patent filing fees
3
3
65
21
Net cash provided by investing activities
3,889
2,041
11
-5,341
Proceeds from private placement of common stock
-
-
0
14,792
Proceeds from loan facility, net of issuance costs
0
49,081
-
-
Issuance costs associated with private placement
-
-
0
1,058
Repayment of previous credit agreement
0
42,984
-
-
Proceeds from exercise of stock options
0
0
1
32
Employee stock purchase plan ('espp') purchases
437
-
247
0
Net cash provided by financing activities
437
6,097
248
13,766
Net decrease in cash and cash equivalents
830
-1,934
-5,179
3,206
Cash and cash equivalents beginning of the period
8,309
10,243
15,422
14,050
Cash and cash equivalents end of the period
9,139
8,309
10,243
15,422
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of marketablesecurities$4,000K (-81.82%↓ Y/Y)Employee stock purchaseplan ('espp')...$437K (-20.26%↓ Y/Y)Net cash provided byinvesting activities$3,889K (-78.13%↓ Y/Y)Net cash provided byfinancing activities$437K (-52.60%↓ Y/Y)Canceled cashflow$111K Net decrease in cashand cash...$830K (145.26%↑ Y/Y)Canceled cashflow$3,496K Purchase of plant andequipment$108K (-85.50%↓ Y/Y)Patent filing fees$3K (-76.92%↓ Y/Y)Stock-based compensation$1,988K (-62.97%↓ Y/Y)Accrued wages and fringebenefits$951K (137.89%↑ Y/Y)Other currentliabilities$911K (326.05%↑ Y/Y)Inventory-$765K (-194.44%↓ Y/Y)Depreciation andamortization$605K (-43.62%↓ Y/Y)Non-cash lease expense$240K (-45.21%↓ Y/Y)Current non-qualifieddeferred compensation...$234K (113.69%↑ Y/Y)Loss on fixed assetdisposal-$188K (45.19%↑ Y/Y)Corporate-owned life insurance('coli') asset-$187K (53.94%↑ Y/Y)Non-cash changes in thefair value of nqdc...-$135K (-112.31%↓ Y/Y)Excess and obsoleteinventory related charges-$65K (88.03%↑ Y/Y)Provision for creditlosses$14K (333.33%↑ Y/Y)Remeasurement and foreigncurrency transaction...-$10K Trade and otherreceivables$5K (-99.64%↓ Y/Y)Net cash used inoperating activities-$3,496K (82.98%↑ Y/Y)Canceled cashflow$6,298K Net loss-$7,663K (67.77%↑ Y/Y)Accounts payable andaccrued expenses-$762K (-184.57%↓ Y/Y)Prepaids and othercurrent assets$721K (292.27%↑ Y/Y)Change in fair value ofloan facility-$211K (-36.13%↓ Y/Y)Operating lease liability-$159K (65.95%↑ Y/Y)Non-qualified deferredcompensation plan liability-$142K (-108.84%↓ Y/Y)Other long-termassets$60K (-79.59%↓ Y/Y)Amortization of premium ofmarketable securities-$43K (77.72%↑ Y/Y)Change in fair value ofwarrant liabilities-$24K (98.43%↑ Y/Y)Contract liabilities-$9K (47.06%↑ Y/Y)Other income, net$688K (-59.36%↓ Y/Y)Total revenues$21,702K (-41.24%↓ Y/Y)Loss before incometaxes-$7,630K (67.90%↑ Y/Y)Income tax expense$33K (175.00%↑ Y/Y)Canceled cashflow$688K Gross profit$17,767K (-41.99%↓ Y/Y)Canceled cashflow$3,935K Operating loss-$6,855K (70.16%↑ Y/Y)Interest expense$1,463K (-41.13%↓ Y/Y)Canceled cashflow$17,767K Purchases of inventory$3,483K (-39.69%↓ Y/Y)Other cost of sales$452K (-14.39%↓ Y/Y)Total operatingexpenses$24,622K (-54.07%↓ Y/Y)Sales and marketing$13,573K (-53.43%↓ Y/Y)General andadministrative$5,971K (-54.27%↓ Y/Y)Research and development$5,078K (-55.46%↓ Y/Y)

AVITA Medical, Inc. (RCEL)

AVITA Medical, Inc. (RCEL)